Actavis Inc. said today it has received Food and Drug Administration approval of its abbreviated new drug application for its treatment for opioid dependence. The drug is the generic equivalent of Reckitt Benckiser's Suboxone.
Actavis, which has its headquarters in Parsippany, said it intends to begin shipment of the product immediately. For the 12 months ending Dec. 31, Suboxone tablets had total U.S. sales of approximately $625 million, according to an announcement by Actavis.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy